Pacific Biosciences reported a revenue increase of 19% year-over-year, driven by growth in sequencing revenue. The company highlighted the strong performance of its Revio system and advancements in its chemistry, contributing to improved data quality and throughput. While operating expenses remain significant, the company is focused on driving further adoption of its platforms and expanding its market presence.
Revenue increased 19% year-over-year to $38.8 million.
Sequencing revenue grew, driven by Revio system sales and utilization.
Made advancements in chemistry to enhance data quality and throughput.
Focused on driving adoption of platforms and expanding market presence.
PacBio anticipates revenue between $170 million and $200 million for the full year 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance